DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma:
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B Summary The DisTinGuish trial Part B investigated the combination of DKN-01, a DKK1 inhibitor, and tislelizumab, an anti-PD-1 antibody, as Read More